Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919122 · ClinicalTrials.gov registry record
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
A clinical trial of Metastatic Renal Cell Carcinoma, sponsored by Duke University.
- Active
- Registry status
- 468
- Enrollment target
- 14
- Study locations
NCT04919122: Active study of Metastatic Renal Cell Carcinoma, sponsored by Duke University.
NCT04919122 is a study of Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by Duke University. The registered enrollment target is 468 participants, above the 131-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (257% higher). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04919122, a study of Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- 468 participants
- Enrollment target
- 14
- Study locations
Study Summary
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
Primary Outcome
Patient's report their medication at each study visit.
Conditions Studied
Study Locations (14)
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
- Duke University - Durham
Pennsylvania
- Geisinger Clinic - Danville
- University of Pittsburgh - Pittsburgh
Iowa
- State University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Ochsner Clinic Foundation d/b/a Ochsner Health - New Orleans
Maryland
- The Johns Hopkins University - Baltimore
Michigan
- The Regents of the University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT04919122 still lists
NCT04919122 is an observational study that tracks outcomes without assigning an intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, above the 131-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (257% higher).
The record links to 1 condition, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04919122 lists 14 locations in 12 states (North Carolina, Pennsylvania, Iowa).
Frequently Asked Questions
What is clinical trial NCT04919122 about?
NCT04919122 is a clinical study titled "Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma". ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
What is the current status of trial NCT04919122?
This trial is currently active not recruiting. The enrollment target is 468 participants. The study started on 2022-04-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04919122 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma.
Who is sponsoring clinical trial NCT04919122?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919122 being conducted?
This trial has 14 study locations across Iowa, Kansas, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04919122's enrollment target sits among peer trials
468 4th of 37 higher than 34 of 37 other Metastatic Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI